{'text': 'AbbVie Announces Late-Breaking Results from Phase 3 Trial of HUMIRA® (adalimumab) in Hidradenitis Suppurativa (HS) Patients at the European Dermatology and Venereology Congress', 'publisher': {'href': 'https://www.multivu.com', 'title': 'MultiVu'}, 'created_at': 'Mon, 13 Oct 2014 07:00:00 GMT', 'description': 'AbbVie Announces Late-Breaking Results from Phase 3 Trial of HUMIRA® (adalimumab) in Hidradenitis Suppurativa (HS) Patients at the European Dermatology and Venereology Congress  MultiVu', 'url': 'https://news.google.com/rss/articles/CBMipAFBVV95cUxOd1FhMEZMZTBhRHM0M1dxM1Joc2FPeHo3ek9rdG5tVmVncmpsVUEybF9BaXI4NmxhTHU4U3JhX3pKOXU2YkdEZHU5Z0lJYWxSdy1KLTI5TndfQndvX0ZiZ3pEcHV5ZER5cURMM2VTb0l1M3lYWWxsMTVHal9sRUJEcG1ZOTd3bnMxNkdCTU5jLXVfeG1SeXlsczRPdWVBYm1tb1pmbQ?oc=5&hl=en-US&gl=US&ceid=US:en'}
